Document is current

Article History

Received: 30 March 2022

Accepted: 30 May 2022

First Online: 22 June 2022

Declarations

:

: Approval by the local ethics committee (Ethikkommission des Fachbereich Medizin, Justus-Liebig-Universität Giessen) was granted before initiating enrollment (AZ 126/21). Written informed consent was obtained from the patients by a member of the research team.

: The data that support the findings of this study are available from the corresponding authors upon reasonable request.

: KS is an employee of AID/GenID, the manufacturer of the ELISpot assay. None of the other authors declare any competing interests.

: There was no funding source for this study. The dot plot arrays were generously supplied and analyzed by AID/GenID GmbH, Straßberg, Germany.

: Study concept and design: HK, KS, CN, HS, CGS, MS, H-WB, and FH-S. FH-S is the senior author of the paper. Literature research and clinical advice: KS, VA, MA, KS, BC, IE, JC, CN, MW, HS, CGS, SJ, CR, WS, RW, MS, H-WB, and FH-S. Acquisition, analysis, or interpretation of data: KS, VA, MA, KS, BC, IE, JC, CN, MW, HS, CGS, SJ, CR, WS, RW, MS, H-WB, and FH-S. Drafting of the manuscript: HK, MA, KS, and FH-S. Critical revision of the manuscript for important intellectual content: KS, VA, MA, KS, BC, IE, JC, CN, MW, HS, CGS, SJ, CR, WS, RW, MS, H-WB, and FH-S. Preparation of figures: KS. Statistical analysis: MA. Study supervision: HK, H-WB, and FH-S. The authors shared study design, data collection, data analyses, and data interpretation, as well as preparation, review, and approval of the manuscript. The authors declare that the results presented in this paper have not been published previously in whole or part. The corresponding authors had full access to all study data and had final responsibility for the decision to submit for publication.